Oncotelic Therapeutics Statistics
Total Valuation
Oncotelic Therapeutics has a market cap or net worth of 10.96 million. The enterprise value is 23.02 million.
| Market Cap | 10.96M |
| Enterprise Value | 23.02M |
Important Dates
The next estimated earnings date is Friday, April 11, 2025.
| Earnings Date | Apr 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Oncotelic Therapeutics has 407.29 million shares outstanding. The number of shares has increased by 2.81% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 407.29M |
| Shares Change (YoY) | +2.81% |
| Shares Change (QoQ) | +1.42% |
| Owned by Insiders (%) | 49.06% |
| Owned by Institutions (%) | n/a |
| Float | 187.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.24 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.94 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01, with a Debt / Equity ratio of 1.59.
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | 1.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.53 |
Financial Efficiency
Return on equity (ROE) is -48.63% and return on invested capital (ROIC) is -1.26%.
| Return on Equity (ROE) | -48.63% |
| Return on Assets (ROA) | -1.01% |
| Return on Capital (ROIC) | -1.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -211,772 |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.47% in the last 52 weeks. The beta is -0.22, so Oncotelic Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | -0.22 |
| 52-Week Price Change | -18.47% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 45.05 |
| Average Volume (20 Days) | 134,701 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -458,022 |
| Pretax Income | -4.92M |
| Net Income | -4.66M |
| EBITDA | n/a |
| EBIT | -458,022 |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 149,018 in cash and 12.94 million in debt, giving a net cash position of -12.79 million or -0.03 per share.
| Cash & Cash Equivalents | 149,018 |
| Total Debt | 12.94M |
| Net Cash | -12.79M |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | 8.13M |
| Book Value Per Share | 0.02 |
| Working Capital | -16.12M |
Cash Flow
| Operating Cash Flow | -1.01M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncotelic Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.81% |
| Shareholder Yield | -2.81% |
| Earnings Yield | -43.05% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Oncotelic Therapeutics has an Altman Z-Score of -2.29. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.29 |
| Piotroski F-Score | n/a |